RE: N4p8 Jul 2021 11:12
Translation re sharecast:
The AIM-listed company said that in addition to investigating tolerability, the goal of the study, funded through a biomedical catalyst grant, was to determine the in vivo ability of the company's SiNPs to deliver DNA to generate local expression of a protein.
He said it was a "key indicator" of whether a vaccine administration system was likely to successfully generate an immune response.
The company said it completed two tests in the study: the first was an injection directly into a cancerous tumor and the second was a subcutaneous injection, two routes of administration that it said were typically used for vaccination.
He concluded that a single injection of SiNP was effective in administering DNA to generate localized protein expression at the injection site, and draining lymph nodes and releasing cytokines into the systemic circulation.
All of them were said to be "crucial elements" to the success of cancer therapy treatment, and the company added that no tolerability issues were found during the duration of the study.
As a result of those results, more in vivo studies would be conducted to demonstrate the ability of the company's SiNPs to deliver specific antigens to promote an adaptive immune response, or to deliver functional proteins that could have a biological effect, and to conduct comparative studies showing how SiNPs compared to lipid nanoparticles , which are currently widely used as systems for administering vaccines and cancer therapies.
"In addition to preparing to bring our sildenafil reformulation to the clinic, we have been analyzing the potential of our nuvec® management system and continue to make encouraging progress demonstrating its capability," said Nigel Theobald, CEO of N4 Pharma.
"This is another important step forward on the road to commercialization of nuvec."
Theobald said the company now has evidence that its SiNPs have "many desirable characteristics" for use in a vaccine approach or to deliver therapeutic proteins to tissues, and they are discovering "key business advantages" compared to lipid nanoparticles.
"This increases the scope of nuvec's application, which in turn enhances the value of the technology for potential business partners."
He added that the value of the global nanotechnology drug supply market was forecast to increase from $4.1 billion in 2014 to $11.9 billion in 2023.
"As nuvec continues to meet its technical objectives, it is very clear that we have the potential to become a major player in this growing market.
"We will continue its development to determine the best way to compete and advance technology."
Sign In
Follow the stocks
